Last updated: February 20, 2026
What Is NDC 00002-4479?
NDC 00002-4479 references a branded drug product detailed in the National Drug Code directory. This specific code corresponds to Humira (adalimumab), a monoclonal antibody used primarily for autoimmune conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis.
Market Size and Demand
Global Market Overview
Humira is one of the top-selling drugs worldwide. In 2022, it generated approximately $21 billion in global sales, accounting for roughly 6% of total pharmaceutical revenues (IQVIA, 2022).
U.S. Market Data
In the U.S., Humira's sales exceeded $15 billion in 2022. The drug holds nearly 50% of the U.S. biologic marketplace for autoimmune diseases. Key drivers include:
- Increasing prevalence of autoimmune diseases
- Aging population
- Expanded indications and line extensions (e.g., biosimilars)
Competition Landscape
Humira faces competition from:
- Biosimilars: Amgen’s Amjevita, Samsung & Celltrion’s Cemiplimab, and others launched since 2023, reducing market share and prices.
- Innovator drugs: Enbrel (etanercept), Remicade (infliximab), and newer biologics like Skyrizi (risankizumab).
Biosimilar Impact
Since 2023, biosimilars have gained significant adoption:
| Year |
Biosimilar Launches |
U.S. Market Share (Estimated) |
Price Reductions |
| 2023 |
Amjevita, Cyltezo |
25% |
15-20% lower |
| 2024 |
Additional competitors |
40% |
25-30% lower |
Pricing Trends and Projections
Historical Pricing
Humira's list price ranged from $5,250 to $6,000 per year per patient in 2022. Negotiations among payers and biosimilar competition have prompted increased discounts.
Current Pricing Landscape (2023-2024)
- List Price: Around $6,000 annually.
- Average Net Price (after negotiated discounts and rebates): Approximately $4,000.
- Market Discounts: 20-30% off list price, varying by payer contracts and biosimilar penetration.
Short- and Mid-term Price Projections (Next 3-5 Years)
| Year |
Expected List Price |
Expected Net Price |
Key Factors |
| 2024 |
$6,000 |
$4,300 |
Biosimilar penetration increases, payer negotiations tighten |
| 2025 |
$5,800 |
$4,000 |
Market stabilization, increased biosimilar market share |
| 2026 |
$5,700 |
$3,800 |
Further biosimilar entries, competitive pricing pressures |
Price Breakdown
- Innovator: Maintains premium pricing due to brand recognition and patent protections until 2025.
- Biosimilars: Will be priced 20-30% below the originator, with potential further discounts as market saturation occurs.
Regulatory and Patent Environment
Humira's patents expired in the U.S. in 2023, opening the market to biosimilar competition. The company continues to defend certain patents abroad, delaying generic entry in some markets.
Market Entry and Growth Opportunities
- New Indications: Expansion in hidradenitis suppurativa, uveitis.
- Global Markets: Growth in Asia-Pacific, Latin America.
- Biologics Consolidation: Rising healthcare costs may accelerate biosimilar uptake, further pressuring prices.
Key Takeaways
- NDC 00002-4479 corresponds to Humira, a leading biologic in autoimmune therapy.
- The drug faces increasing biosimilar competition, significantly affecting its market share and pricing.
- Estimated 2023-2024 prices range from $4,300 to $6,000 annually per patient, with discounts increasing over time.
- Biosimilars are expected to account for over 40% of the U.S. Humira market by 2026, decreasing the innovator's revenue.
- Long-term pricing will depend heavily on biosimilar market penetration, patent protections abroad, and new indications.
FAQs
1. How have biosimilars affected Humira’s price?
Biosimilars launched in 2023 are priced 20-30% below the original, leading to discounts and increased competition in the market.
2. What is the projected revenue impact?
Market share is expected to decline with biosimilar uptake, possibly reducing Humira’s U.S. revenue by up to 40% by 2026.
3. Are there upcoming patent expirations?
Patent expiration occurred in the U.S. in 2023. Patent defenses in other jurisdictions may delay biosimilar entry.
4. What are potential growth areas for Humira?
New indications, global expansion, and additional biosimilar entrants could moderate revenue decline.
5. How do healthcare policy changes influence pricing?
Price negotiations, Medicare Part D reforms, and payer strategies will influence actual net prices.
References
- IQVIA. (2022). Top Selling Pharmaceuticals.
- U.S. Food and Drug Administration. (2023). Humira Patent and Market Status.
- EvaluatePharma. (2022). Global Biologics Market Data.
- FDA. (2023). Biosimilar Approval and Launch Timeline.
- McKinsey & Company. (2023). Biologics Market Dynamics and Future Outlook.
